# Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

> **NCT07180056** · — · RECRUITING · sponsor: **Wenjin Yin** · enrollment: 229 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** CDK4/6 inhibitor

## Key facts

- **NCT ID:** NCT07180056
- **Lead sponsor:** Wenjin Yin
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-28
- **Primary completion:** 2028-02
- **Final completion:** 2033-02
- **Target enrollment:** 229 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07180056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07180056, "Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07180056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*